vga039
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 16, 2023 (NCT05776069)
Timeline
Indications
Studied for
Mechanism of action
- Vitamin K-dependent protein SMODULATOR
PROS1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07115004 | Phase 3 | Oct 15, 2025 | Vega Therapeutics, Inc |
| NCT05776069 | Phase 1 | Mar 16, 2023 | Vega Therapeutics, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vega Therapeutics, Inc | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1